RT Journal Article SR Electronic T1 A phase I/II trial to treat massive Africanized honeybee (Apis mellifera) stings using the new apilic antivenom JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.12.26.20248062 DO 10.1101/2020.12.26.20248062 A1 Barbosa, Alexandre Naime A1 Ferreira, Rui Seabra A1 de Carvalho, Francilene Capel Tavares A1 Schuelter-Trevisol, Fabiana A1 Mendes, Mônica Bannwart A1 Mendonça, Bruna Cavecci A1 Batista, José Nixon A1 José Trevisol, Daisson A1 Boyer, Leslie A1 Chippaux, Jean-Philippe A1 Medolago, Natália Bronzatto A1 Cassaro, Claudia Vilalva A1 Rigotto Carneiro, Márcia Tonin A1 de Oliveira, Ana Paola Piloto A1 Pimenta, Daniel Carvalho A1 da Cunha, Luís Eduardo Ribeiro A1 dos Santos, Lucilene Delazari A1 Barraviera, Benedito YR 2021 UL http://medrxiv.org/content/early/2021/01/03/2020.12.26.20248062.abstract AB Safety, optimal minimum dose, and, preliminary effectiveness of a new generation Africanized honeybees (Apis mellifera) antivenom (AAV) were evaluated. A phase I/II, multicenter, non- randomized, single-arm clinical trial involving 20 participants showing multiple stings were studied. Participants have received either 2 to 10 vials of AAV based on the stings number together with a predefined adjuvant, symptomatic, and complementary treatment schedule. The primary safety endpoint was the presence of early adverse reactions within the first 24 hours after treatment. Preliminary efficacy through clinical evolution, including laboratory tests, was assessed at baseline and over the following four weeks. ELISA assays and mass spectrometry estimated the venom pharmacokinetics before, during, and after treatment. Twenty adult participants, 13 (65%) males, and 7 (35%) females, with a median age of 44 years and a mean body surface of 1.92 m2 (median = 1.93 m2) were recruited. The median number of stings was 52.5 ranging from 7 to more than 2,000. Envenoming severity was classified as 80% mild, 15% moderate, and 5% severe. According to the protocol, 16 (80%) participants received two AAV vials, 3 (15%) six vials, and one (5%) 10 vials. There was no discontinuation of the treatment due to acute adverse events and there were no late adverse reactions. Two patients showed mild adverse events with only transient itchy skin and erythroderma. All participants completed the infusion within two hours and there was no loss of follow-up after discharge. ELISA assays showed venom concentrations varying between 0.25 ng/mL and 1.479 ng/mL prior to treatment. Venom levels decreased in all cases during the hospitalization period. Surprisingly, in nine cases (45%), despite clinical recovery and without symptoms, the venom levels increased again during outpatient care 10 days after discharge. Mass spectrometry showed melittin in eight participants 30 days after the treatment. Considering the promising safety results of the investigational product for the treatment of massive Africanized honeybee attacks, added to efficacy in clinical improvement and immediate decrease in blood venom level, the AAV has shown to be safe for human use.Trial registration Universal Trial Number (UTN): U1111-1160-7011, Register Number: RBR-3fthf8 (http://www.ensaiosclinicos.gov.br/rg/RBR-3fthf8/).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialTrial registration: Universal Trial Number (UTN): U1111-1160-7011, Register Number: RBR-3fthf8 (http://www.ensaiosclinicos.gov.br/rg/RBR-3fthf8/).Clinical Protocols http://dx.doi.org/10.1186/s40409-017-0106-y Funding StatementThis study was supported by the National Council of Technological and Scientific Development (CNPq) under Grants No. 437089/2018-5 (LDS), 563582/2010-3 (BB), 401170/2013-6 (BB), and in part by grants from CAPES (Coordination for the Improvement of higher Education Personnel) [AUX-PE Toxinology Proc. No. 23,038.000823/201121]. RSF Jr. is a CNPq PQ1C fellow researcher [303224/2018-5]. DCP is a CNPq fellow researcher [301974/2019-5].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The clinical protocol has been previously approved by the Brazilian National Commission on Ethics in Research (CONEP, Certificate of Presentation of Ethical Appreciation No. 19006813.4.1001.5411, v7, approved in 06/07/2016) and the Brazilian National Health Surveillance Agency (ANVISA) whose Consent Record of Apis Study was approved on 02/05 2016 by No. 0907532142, Proc. No. 25361611582201493. This trial RBR-3FTHF8 was registered in 2015 in the Brazilian Clinical Trials Registry (ReBEC) at http://www.ensaiosclinicos.gov.br/. The first participant was included in 08/22/2016, the Universal Trial Number (UTN) is U1111-1160-7011, the Register Number is RBR-3fthf8 and the public access URL is available at http://www.ensaiosclinicos.gov.br/rg/RBR-3fthf8/ (24) The clinical trial protocol was published by Barbosa et al. in 2017 and is available at https://doi.org/10.1186/s40409-017-0106-y.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe additional files will be able just on Article Published!